Varenicline Versus Cytisine for Smoking Cessation in Primary Care Setting

PHASE3CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

September 15, 2022

Study Completion Date

November 1, 2022

Conditions
Smoking Cessation
Interventions
DRUG

Varenicline

191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling

DRUG

Cytisine

185 patients will receive cytisine for 25 days and regular phone calls with brief counseling

Trial Locations (2)

1000

University of Ljubljana School of Medicine, Ljubljana

10000

University of Zagreb School of Medicine, Zagreb

All Listed Sponsors
collaborator

University of Ljubljana School of Medicine, Slovenia

OTHER

collaborator

University of Zagreb School of Medicine

UNKNOWN

collaborator

Harvard Medical School (HMS and HSDM)

OTHER

lead

University of Zagreb

OTHER

NCT04015414 - Varenicline Versus Cytisine for Smoking Cessation in Primary Care Setting | Biotech Hunter | Biotech Hunter